Bioton Values Glaxo Deal at Up to $600 Million, CEO Tells Puls

Dec. 20 (Bloomberg) -- Bioton SA of Poland estimates the value of a distribution deal with GlaxoSmithKline Plc at as much as $600 million, Puls Biznesu reported, citing Bioton Chief Executive Officer Slawomir Ziegert.

Bioton announced the 15-year agreement, under which the U.K.-based company will distribute the Polish producer’s insulin in Russia, in a regulatory statement on Dec. 18.

To contact the reporter on this story: Pawel Kozlowski in Warsaw pkozlowski@bloomberg.net

To contact the editor responsible for this story: Gavin Serkin at gserkin@bloomberg.net